Treatment of Vulvar Leukoplakia

Primary Treatment Recommendation

The British Journal of Dermatology recommends first-line treatment for vulvar leukoplakia (lichen sclerosus) with ultrapotent topical corticosteroid therapy using clobetasol propionate 0.05% ointment, applied once daily for 1 month, alternate days for 1 month, and then twice weekly for 1 month 1

Establish diagnosis clinically or obtain histological confirmation via biopsy to rule out malignancy, particularly squamous cell carcinoma which occurs in 3.5-5% of lichen sclerosus cases, as recommended by Praxis Medical Insights 2
Document architectural changes at baseline using diagrams or photographs, and assess for dyspareunia, psychosexual dysfunction, and urinary symptoms, as recommended by the British Journal of Dermatology 1

Prescribe clobetasol propionate 0.05% ointment with a structured 3-month regimen: once daily for 1 month, alternate days for 1 month, and then twice weekly for 1 month, as recommended by the British Journal of Dermatology 1
Combine with soap substitute and barrier preparation, and educate patients on the amount to use, application site, and safe use of ultrapotent steroids, as recommended by the British Journal of Dermatology 1

Consider intralesional triamcinolone (10-20 mg) for hyperkeratotic areas that fail topical steroids, but only after biopsy excludes intraepithelial neoplasia or malignancy, as recommended by the British Journal of Dermatology 1

Reserve surgery for cases with confirmed malignancy, severe architectural distortion causing functional impairment unresponsive to medical therapy, or biopsy-confirmed intraepithelial neoplasia, as recommended by the British Journal of Dermatology 1

Follow up all treated patients to assess response and advise on long-term control, and refer to specialist vulvar clinic if not responding to topical steroids or if surgical management is considered, as recommended by the British Journal of Dermatology 1
Long-term surveillance is mandatory given 3.5-5% malignant transformation risk, as recommended by Praxis Medical Insights 2

Continue individualized topical steroid regimen for ongoing active disease despite good compliance, and adjust frequency based on clinical response, maintaining control of symptoms and preventing scarring, as recommended by the British Journal of Dermatology 1

Do not perform vulvectomy as first-line treatment, and do not skip biopsy when malignancy is suspected, as recommended by Praxis Medical Insights 2
Do not use intralesional steroids without first obtaining biopsy to exclude neoplasia, and do not discontinue treatment prematurely, as recommended by the British Journal of Dermatology 1
Avoid all irritant and fragranced products which can exacerbate symptoms, as recommended by the British Journal of Dermatology 1

All patients should be managed by healthcare professionals experienced in treating vulvar conditions, and provide patients with up-to-date educational materials on the condition, as recommended by the British Journal of Dermatology 1